Advertisement

ADVERTISEMENT

breast cancer

Research in Review
Neoadjuvant Endocrine Therapy for Breast Cancer Produces Same Results as Combination Chemotherapy
07/08/2016
JCP Editors
Neoadjuvant endocrine therapy (NET) may be associated with similar response rates as neoadjuvant combination chemotherapy, but with significantly lower toxicity, findings from a study published in JAMA Oncology...
Neoadjuvant endocrine therapy (NET) may be associated with similar response rates as neoadjuvant combination chemotherapy, but with significantly lower toxicity, findings from a study published in JAMA Oncology...
...
07/08/2016
Journal of Clinical Pathways
Research in Review
Genetic Testing for DCIS Unnecessary, Costing the US Millions
07/05/2016
JCP Editors
Automatically testing all core needle biopsy specimens showing ductal carcinoma in situ (DCIS) for estrogen receptor (ER) and progesterone receptor (PR) is highly expensive and may not be needed, according to a study...
Automatically testing all core needle biopsy specimens showing ductal carcinoma in situ (DCIS) for estrogen receptor (ER) and progesterone receptor (PR) is highly expensive and may not be needed, according to a study...
...
07/05/2016
Journal of Clinical Pathways
Research in Review
Breast Cancer Treatment May Lead to Functional Decline or Death in Elderly Patients
07/01/2016
JCP Editors
Many older women diagnosed with nonmetastatic breast cancer may experience functional decline or death within 12 months of breast cancer treatment initiation, but the Vulnerable Elders Survey (VES-12) may help to...
Many older women diagnosed with nonmetastatic breast cancer may experience functional decline or death within 12 months of breast cancer treatment initiation, but the Vulnerable Elders Survey (VES-12) may help to...
Many...
07/01/2016
Journal of Clinical Pathways
Research in Review
Shortened Radiotherapy for Breast Cancer Supported in Study
06/22/2016
JCP Editors
A shortened course of radiotherapy for patients with early stage breast cancer may actually produce slightly better outcomes than the conventional protocol, according to the results of a randomized clinical...
A shortened course of radiotherapy for patients with early stage breast cancer may actually produce slightly better outcomes than the conventional protocol, according to the results of a randomized clinical...
A...
06/22/2016
Journal of Clinical Pathways
Clinical Insights
Cryoablation of Benign and Malignant Breast Tumors
06/21/2016

Geetika Klevos, MD; Fernando Collado-Mesa, MD; Jose M. Net, MD; Monica M. Yepes, MD

From Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida.

Geetika Klevos, MD; Fernando Collado-...
Abstract: Cryoablation is a well established, FDA approved, minimally invasive treatment modality for fibroadenomas. Additionally, several pilot studies have shown its success in the treatment of small breast cancers. It is an outpatient...
Abstract: Cryoablation is a well established, FDA approved, minimally invasive treatment modality for fibroadenomas. Additionally, several pilot studies have shown its success in the treatment of small breast cancers. It is an outpatient...
Abstract: Cryoablation is a well...
06/21/2016
IO Learning
Research in Review
Breast Cancer Biomarker of Chemotherapy Resistance Identified
05/26/2016
JCP Editors
Expression of methylation-controlled J protein (MCJ) may be an indicator of successful outcomes and reduced risk of relapse in patients with breast cancer, according to a recent study. Chemotherapy is a key part of...
Expression of methylation-controlled J protein (MCJ) may be an indicator of successful outcomes and reduced risk of relapse in patients with breast cancer, according to a recent study. Chemotherapy is a key part of...
...
05/26/2016
Journal of Clinical Pathways
Research in Review
Costs of Adverse Events Quantified for Breast Cancer Patients
05/24/2016
JCP Editors
Adverse events (AEs) may be a driver of high health care costs in patients with metastatic breast cancer treated with systemic therapy, according to a new study. AEs are a serious concern for patients and providers,...
Adverse events (AEs) may be a driver of high health care costs in patients with metastatic breast cancer treated with systemic therapy, according to a new study. AEs are a serious concern for patients and providers,...
...
05/24/2016
Journal of Clinical Pathways
News
Concure Oncology Launches One-Time, One-Day Radiation Treatment for Early-Stage Breast Cancer
05/12/2016
Breast Microseed Treatment Enables Women to Get Back to Living Their Lives the Very Next DaySEATTLE, May 12, 2016 /PRNewswire-USNewswire/ -- Concure Oncology/Breast Microseed, Inc., a company specializing in early-stage breast cancer...
Breast Microseed Treatment Enables Women to Get Back to Living Their Lives the Very Next DaySEATTLE, May 12, 2016 /PRNewswire-USNewswire/ -- Concure Oncology/Breast Microseed, Inc., a company specializing in early-stage breast cancer...
Breast Microseed Treatment...
05/12/2016
IO Learning
Research in Review
FACT-B Most Effective Health-Related Quality of Life Instrument for Breast Cancer
05/06/2016
JCP Editors
Results from a study evaluating different tools intended to measure patient-reported health-related quality of life (HRQoL) in patients with breast cancer suggest that the Functional Assessment of Cancer...
Results from a study evaluating different tools intended to measure patient-reported health-related quality of life (HRQoL) in patients with breast cancer suggest that the Functional Assessment of Cancer...
...
05/06/2016
Journal of Clinical Pathways
Research in Review
Hormone Therapy More Cost-Effective Than Chemotherapy for Patients With HR+/HER2- Metastatic Breast Cancer
05/06/2016
JCP Editors
A study of patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) metastatic breast cancer has found that treatment with first-line chemotherapy offers no survival...
A study of patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) metastatic breast cancer has found that treatment with first-line chemotherapy offers no survival...
...
05/06/2016
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
October 26 ⁠–⁠ October 27
October 29 ⁠–⁠ November 2
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use